

SHL/SEC/2022

July 20, 2022

The Bombay Stock Exchange Limited Listing Department, 1<sup>st</sup> Floor, New Trading Ring, Rotunda Building, Phiroze JeeJeeBhoy Towers, Dalal Street, Fort Mumbai – 400 001. The Calcutta Stock Exchange Ltd. 7, Lyons Range Kolkata - 700 001 India

Company Code: 537253

Dear Sir,

### Sub.: Outcome of the 249<sup>th</sup> Board Meeting held on 20.07.2022.

Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we are pleased to inform, inter-alia the outcome of the Meeting of the Board of Directors of the Company held on Wednesday, July 20, 2022, the meeting was started at **05:00p.m**., and concluded at **6:45 p.m**.

- 1. Approved Unaudited Financial Results (Standalone & consolidated) for the 01<sup>st</sup> quarter ended June 30, 2022 of the Financial Year 2022-23 and noted Limited Review Report on the same (Copy enclosed as Annexure-1).
- (a)Noted registration of Charge ID100578282 w.e.f 06.05.2022 in favor of BMW INDIA FINANCIAL SERVICES PRIVATE LIMITED vehicle loan
   (b) Noted Registration of Charge ID 100580093 in favour of ICICI Bank for vehicle loan.
   (c) Noted satisfaction charge of Charge ID 100246092 due to repayment of Motor vehicle Loan to ICICI Bank.
- Approved renewal in remuneration of the Chief Financial officer and Company Secretary of the Company, as per terms and conditions mentioned in increment letter issued to them, w.e.f. 01.04.2022
- Recommended Change in designation of Mr. Sanjay Kumar Kaushik, Independent Director (DIN:00329013) to Non-Executive Director.

Name of Director & DIN	Mr. Sanjay Kumar Kaushik,(DIN:00329013)					
Reason for change	Change in designation (subject to approval via Special Resolution by Shareholders in ensuing AGM) as Non- Executive Director.					
Date of change in designation	w.e.f. the date of the 48 <sup>th</sup> AGM i.e. 28.09.2022).					
Brief Profile	Mr. Sanjay is a graduate from Rajasthan University and is an expert in his field. He has been working with Kaneeka Trimurti					



	Minerals Pvt. Ltd and Kaushik Chemicals and has a vast experience of more than 23 years in the field of antifungus lotion.
Disclosure of	Mr. Sanjay Kumar Kaushik, is not related to any of the existing
Relationship with	Directors of the company in any way except himself as Non-
Directors	Executive and Independent Director in the company.

 Recommended appointment of Mrs. Mudita Chaturvedi DIN:02384403) as Non-executive & Independent Director of the Company.

Name of Director & DIN	Mrs. Mudita Chaturvedi, Non-Executive Director (DIN:02384403)							
Reason for change	Appointment (subject to approval via Special Resolution by Shareholders in ensuing AGM) as Independent Director.							
Date of Appointment	5 years from the date of the 48th AGM (w.e.f.28.09.2022)							
Brief Profile	Mrs. Mudita was born in India on 1st November 1981 and graduated in Mass Media and Mass Communication from IP College, Delhi University. She did PG Diploma in Mass media and Mass communication from IGNOU.							
	Ms. Mudita Chaturvedi works as an Independent media consultant. Mudita had over 21 years of experience in Media Industry with demonstrated experience in anchoring, research and writing, scripting and packaging shows and social media management both in India and the USA.							
	She is Independent Media consultant for Projects for ICAI and Bhartiya Kala Kendra, Media consultant with PHDCCI, Media consultant and Director to Morris Street Advisors Pvt. Ltd freelance consultant to T V Asia (New York) and corresponden and News anchor for Zee News (Delhi & New York).							
	She is also enrolled herself with database of Independent Directors maintained by Institute of Corporate Affairs, Manesar to act as Independent Director and Confirm the Compliance of Rul 6(1) and 6(2) of the Companies (Appointment and Qualification of Directors) Rules, 2014. Her registration no. with Institute of Corporate Affairs is IDDB-DI-202207-043373, which is valid from July 12, 2022 to July 11, 2027.							
Disclosure o Relationship with Directors	f Mrs. Mudita Chaturvedi is not related to any of the existin Directors of the company in any way except herself as Non Executive Director in the company.							



### **Sunil Healthcare Limited**

Vijay Tower, 38E/252 - A, Shahpur Jat, Panchsheel Park Commercial Complex, New Delhi-110049 (INDIA) T: +91 11 49435555/00 E-mail: info@sunilhealthcare.com Web.: www.sunilhealthcare.com CIN No.: L24302DL1973PLC189662



- Approved appointment of M/s. Link Intime India Private Limited, New Delhi an agency to conduct Remote e-voting/e-voting and Video conferencing for ensuing the 48<sup>th</sup> Annual General Meeting to be held on Wednesday, September 28, 2022.
- Approved appointment of Mr. Tara Chand Sharma (FCS-5749 and C.P. No. 4078) Proprietor of M/s. Jain Sharma & Associate, Company Secretaries, Jaipur as Scrutinizer for conducting e-voting for the 48<sup>th</sup> Annual General Meeting.
- 8. Fixed Book Closure period from 21.09.2022 to 28.09.2022 for the purpose of ensuing Annual General Meeting to be held on Tuesday 28.09-2022 at registered office of the Company, New Delhi.
- 9. Fixed the date of ensuing Annual General Meeting to be held on Wednesday, 28.09.2022 at Registered office at 38E/252A, Vijay Tower, 3rd Floor, Panchsheel Commercial Complex, Shahpur Jat, New Delhi-110049 through video conferencing/other Audio Visual Method and approved the Cut-off date for determining the entitlements of Members to attend and vote at AGM will be September 20, 2022 and for sending of notice 29.07.2022.
- Noted resignation of Mr. Santosh Kumar Sharma, Company Secretary, KMP & Compliance officer and DGM-Legal of the Company w.e.f. close of office hours on 10.08.2022.

You are requested to take the above information in your record and oblige us.

Thanking you, Yours sincerely, for **Sunil Healthcare Limited** 

Santosh Kumar Sharma Company Secretary FCS-6817 Date: 20.07.2022 Place: New Delhi Encl.: a/a



Sunil Healthcare Limited

Vijay Tower, 38E/252 - A, Shahpur Jat, Panchsheel Park Commercial Complex, New Delhi-110049 (INDIA) T: +91 11 49435555/00 E-mail: info@sunilhealthcare.com Web.: www.sunilhealthcare.com CIN No.: L24302DL1973PLC189662



SUNIL HEALTHCARE LIMITED

## Registered Office : '38E/252-A, Vijay Tower, Shahpurjat, New Delhi-110049 Email: info@sunilhealthcare.com; website: www.sunilhealthcare.com

#### CIN: L24302DL1973PLC189662

#### STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2022

STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED SUTH JONE 2022 Rs. in La											
Star				Year Ended	Consolidated			Year Ended			
	Quarter ended			Standalone	Quarter ended			Consolidated			
	30th June 2022		30th June 2021	31st March 2022	30th June 2022	31st March 2022	30th June 2021	31st March 2022			
Particulars	Unaudited	Audited (Refer note. 2)	Unaudited	Audited	Unaudited	Audited (Refer note. 2)	Unaudited	Audited			
1 Revenue from Operations	3,408.11	3,070.99	2,623.08	11,637.29	3,340.59	3,168.18	2,655.87	11,916.41			
2 Other Income	33.53	67.61	18.59	155.42	91.73	85.07	24.41	167.55			
3 Total Income (1+2)	3,441.64	3,138.60	2,641.67	11,792.71	3,432.32	3,253.25	2,680.28	12,083.96			
4 Expenses											
a) Cost of Materials consumed	1,253.00	1,143.30	1,002.14	4,290.14	1,253.00	1,143.30	1,002.14	4,290.14			
b) Purchase of Stock-in-trade	0.23	12.13	-	39.99	0.23	12.13	-	39.99			
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(91.32)	(23.25)	153.60	360.72	(113.71)	47.35	161.57	515.15			
d) Employees benefit expenses	390.16	366.77	349.73	1,418.97	390.16	366.77	349.73	1,418.97			
e) Finance Costs	81.88	77.19	106.46	348.88	81.88	77.19	106.46	348.88			
f) Depreciation and amortisation	163.03	156.58	155.34	630.57	163.07	156.62	155.38	630.73			
g) Other Expenses	1,034.66	855.33	837.31	3,746.33	1,075.26	883.46	873.19	3,913.63			
Total Expenses	2,831.64	2,588.05	2,604.58	10,835.60	2,849.89	2,686.82	2,648.47	11,157.49			
5 Profit before tax (3-4)	610.00	550.55	37.09	957.11	582.43	566.43	31.81	926.47			
6 Tax Expenses (Net)	163.25	163.78	9.59	279.43	163.93	165.36	10.97	284.41			
a) Current Tax											
i)-Current Tax	101.82	85.05	33.35	152.39	102.50	86.63	34.00	156.00			
ii)-Tax for Earlier Period	-	(0.91)	-	(0.91)	-	(0.91)	0.73	0.46			
b) Deferred Tax Charged/(Credit)	61.43	79.64	(23.76)	127.95	61.43	79.64	(23.76)	127.95			
7 Profit/(Loss) after tax	446.75	386.77	27.50	677.68	418.50	401.07	20.84	642.06			
8 Other Comprehensive Income (OCI)											
<ul> <li>a) Items that will not be reclassified to Profit or Loss (net of tax)</li> </ul>	-	(5.97)	-	(5.97)	-	(2.25)	-	(5.97)			
b) Items that will be reclassified to Profit or Loss (net of tax)	-	-	-	-	(11.12)	(12.33)	(6.24)	(12.33)			
9 Total Comprehensive Income	446.75	380.80	27.50	671.71	407.38	386.49	14.60	623.76			
10 Paid-up equity share capital (Face value per share Rs.10/-)	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48			
11 Other Equity				4,453.49				3,970.01			
12 Earning per share of Rs.10/- each(not annualised)											
(a) Basic (Rs.)	4.36	3.77	0.27	6.61	4.08	3.91	0.20	6.26			
(b) Diluted (Rs.)	4.36	3.77	0.27	6.61	4.08	3.91	0.20	6.26			

1 As the Company's business fall within a single primary business segment viz. sale of capsule, the disclosure requirement of Indian Accounting Standard (Ind AS-108) "Operating Segments" prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder, is not applicable.

2 The figures for the quarter ended March 31, 2022 are the balance figures between audited figures for the full financial and published year to date figures up to the third quarter of the previous financial year.

3 The figures for the previous periods have been regrouped/ rearranged, wherever considered necessary, to conform current period classifications.

4 The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on July 20, 2022

lan

Anil Khaitan (Chairman cum Managing Director) DIN 00759951

Place: NEW DELHI Date: 20.07.2022

## JKVS&CO. Chartered Accountants

Review Report on unaudited standalone quarterly financial results Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015

### To the Board of Directors of Sunil Healthcare Limited

We have reviewed the accompanying statement of unaudited standalone financial results ("Statement") of Sunil Healthcare Limited (the Company") for the quarter ended June 30, 2022. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: New Delhi Date: July 20, 2022



For JKVS & Co. Chartered Accountants Firm Registration No. 318086E

Sajal Goyal Partner Membership No.523903 UDIN: 22523903 ANHU H&&072

## JKVS&CO. Chartered Accountants

Independent Auditor's Review Report on consolidated unaudited quarterly financial results of Sunil Healthcare Limited, Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, as amended

To Board of Directors of Sunil Healthcare Limited

- We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Sunil Healthcare Limited ('the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended June 30, 2022, ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

- 4. The Statement includes the results of the following entities
  - a. Sunil Healthcare Mexico SA De CV (Incorporated in Mexico)
  - b. Sunil Healthcare North America LLC (Incorporated in USA)
- 5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement read with notes therein, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



209, Hans Bhawan 1, Bahadur Shah Zafar Marg, New Delhi-110002 Email ID : newdelhi@jkagarwal.com 1 9718013372, 9891751595 Office at Kolkata & Mumbai

# JKVS&CO.

6. The consolidated unaudited financial results include the interim financial results of two foreign subsidiaries whose financial statements are not required to review/audit according to the law of respective countries and whose financial results reflect total revenue from operation of Rs. 69.71 Lakhs for the quarter ended June 30, 2022, and profit after tax of Rs. 0.01 Lakhs for the quarter ended June 30, 2022 and total comprehensive income of Rs. (11.12) Lakhs for the quarter ended June \_30, 2022, as considered in the Statement. According to the information and explanations given to us by the Management, these Interim financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

Place: New Delhi Date: July 20, 2022

For JKVS & Co. Chartered Accountants Firm Registration No. 318086E

Sajal Goyal Partner Membership No. 523903 UDIN: 22523903 ANHULX 7209